Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Bulgaria
  4. Bulgaria Stock Exchange
  5. Sopharma AD
  6. News
  7. Summary
    SFA   BG11SOSOBT18

SOPHARMA AD

(SFA)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sopharma : Consolidated financial results for the first quarter of 2021

06/02/2021 | 09:57am EDT

Sopharma Group

Consolidated financial results for the first quarter of

2021

Consolidated financial results for the first quarter of 2021

Who are we?

Sopharma Group

The Group is a leading, vertically-integrated Bulgarian manufacturer, exporter and distributor of

pharmaceutical and other health related products with a strong presence in Southern and Eastern Europe, offering a wide range of prescription and OTC pharmaceutical products and other health related products and services.

The Group works in the following areas:

  • Production of active pharmaceutical ingredients;

Pharmaceutical production;

  • Wholesale and distribution;

Non-pharmaceutical activities.

"Sopharma" AD

Bulgarian based mother company,

pharmaceutical producer

API production

Farmer, Bulgaria

Farming of

medicinal plants

"Sopharma" AD ,

Kazanlak Bulgaria

Extraction of active

ingredients

Pharmaceuticals

production

"Sopharma" AD , Bulgaria Self-developedproducts from herbal origin, Generic products

"Biopharm Engineering"

AD, Bulgaria and PAO

"Vitamini" Ukraine

Generic products

Veterinary products

Wholesale and

distribution

"Sopharma Trading" AD,

Bulgaria and Serbia

Pre-wholesaling, wholesaling, retail

"BRIZ" Latvia and

Sopharma 100% owned subsidiaries in Ukraine, Kazakhstan, Poland and etc.

Wholesaling, retail

Non-pharma activities

"Biopharm Engineering"

AD

Veterinary products, sterile

production

"Momina Krepost" AD

Plastic disposable materials

Brief history and key milestones:

  • Local pharmaceutical community starts construction of the first laboratory for production of medicinal products

• Privatization -

Licensed its production

facilities according to the

"Sopharma" AD

European GMP

becoming a

Increased production capacity

• Listing on Warsaw

privately held

through acquisition of

pharmaceutical

New modern

"Bulgarian Rose Sevtopolis" AD

Stock Exchange

company

pharmaceutical

plant Vrabevo

• Acquired a very

opened for

active distributor

production of

"Briz" OOD in

medicinal

Latvia

products

Transformation

through merger

First generic

between "Medica" AD

in urology -

and "Sopharma" AD

Urimax Duo

  • Transformation

through merger

"Sopharma"AD

between

sold the shares

"Unipharm" AD and

owned by it

"Sopharma" AD

• Focus on

from the capital

of "Aromania"

R&D

AD

1933

1953

1999

2000

2002

2003

2004

2005

2006

2009

2011

2013

2014

2017

2018

2019

2020

  • "Sopharma" AD nationalized

Start of production:

  • 1956 - Nivalin

• 1964 - Tabex

  • 1981 - Tribestan
    • "Sopharma" AD listed on BSE.

Acquired five small

• Construction of new production

"Sopharma Trading" AD

producers:

Opened the state-of-

facilities in Sofia and Serbia

acquires sole control

"Unipharm" AD

the-art logistics

• First successful registration of

"Vramed" AD

terminal for

over the companies

Sopharma's product in old EU

"Pharmachim Holding" AD

distribution of

"SCS Franchise" AD and

(Nivalin in Austria)

"NIHFI" AD

pharmaceutical

"Sanita Franchising" AD

• Control stake acquisition in

"Rostbalkanpharm"

products (European

"Unifarm" AD

GDP certified)

"Sopharma"

• Penetrating into distribution

AD celebrates

its 85th

business by acquiring "Sopharma

anniversary

Trading" AD

Modern history - period of constant modernization and development

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Sopharma AD published this content on 02 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2021 13:56:04 UTC.


ę Publicnow 2021
All news about SOPHARMA AD
08/30SOPHARMA : Consolidated financial results for the first half of 2021
PU
08/30SOPHARMA : Information according to Annex 9 of Ordinance 2 as at 30 June 2021
PU
08/30SOPHARMA : Declaration by the responsible directors as at 30 June 2021
PU
08/30SOPHARMA : Notes to the consolidated financial report as at 30 June 2021
PU
08/30SOPHARMA : Consolidated management report as at 30 June 2021
PU
08/30SOPHARMA : Insider information as at 30 June 2021
PU
08/30SOPHARMA : Additional information as at 30 June 2021
PU
08/30SOPHARMA : Consolidated financial report according to IFRS as at 30 June 2021
PU
08/30Sopharma AD Reports Earnings Results for the Half Year Ended June 30, 2021
CI
07/30SOPHARMA : Individual financial results for the first half of 2021
PU
More news
Financials
Sales 2021 1 536 M 920 M 920 M
Net income 2021 36,6 M 21,9 M 21,9 M
Net Debt 2021 428 M 256 M 256 M
P/E ratio 2021 12,8x
Yield 2021 1,35%
Capitalization 465 M 280 M 279 M
EV / Sales 2021 0,58x
EV / Sales 2022 0,55x
Nbr of Employees 5 483
Free-Float 39,7%
Chart SOPHARMA AD
Duration : Period :
Sopharma AD Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 3,70 BGN
Average target price 3,48 BGN
Spread / Average Target -5,95%
EPS Revisions
Managers and Directors
Ognian Ivanov Donev Chairman, CEO, MD & Executive Director
Boris Anchev Borisov Chief Financial Officer
Iliyan Slavov Kolev Director-Technical Matters
Andrey Liudmilov Breshkov Independent Director
Alexander Victorov Tchaouchev Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SOPHARMA AD15.63%280
WALGREENS BOOTS ALLIANCE, INC.24.42%42 921
JD HEALTH INTERNATIONAL INC.-46.70%32 738
MCKESSON CORPORATION19.45%32 134
CARDINAL HEALTH, INC.-1.85%15 269
SINOPHARM GROUP CO., LTD.8.96%8 241